[ Price : $8.95]
Federal Register notice: FDA announces that a product was approved using a priority review voucher Genentechs Vabysmo (faricimab-...[ Price : $8.95]
CDER and CBER accept the first letter of intent submission for the new Innovative Science and Technology Approaches for New Drugs ...[ Price : $8.95]
After reporting new clinical trial data, Ionis Pharmaceuticals and AstraZeneca plan to submit an NDA for eplontersen for treating ...[ Price : $8.95]
Four drug industry stakeholders ask FDA to clarify elements in a draft guidance on interoperable exchange of information under the...[ Price : $8.95]
Pacira BioSciences plans to submit a supplemental NDA early next year to broaden the label on its post-surgical pain drug Exparel ...[ Price : $8.95]
CBER announces a 10/5 Webinar entitled Study Data Standards Update for CBER: Your Guide to a Successful Submission.[ Price : $8.95]
FDA lifts its clinical hold on Sareptas investigational Duchenne muscular dystrophy drug SRP-5051.[ Price : $8.95]
FDA warns St. Louis, MO-based Leaf of Life that its Web site takes orders for dietary supplements that are legally considered to b...